103 related articles for article (PubMed ID: 28355131)
1. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates.
Shinkai Y; Kashihara S; Minematsu G; Fujii H; Naemura M; Kotake Y; Morita Y; Ohnuki K; Fokina AA; Stetsenko DA; Filichev VV; Fujii M
Nucleic Acid Ther; 2017 Jun; 27(3):168-175. PubMed ID: 28355131
[TBL] [Abstract][Full Text] [Related]
2. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
3. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
4. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
[TBL] [Abstract][Full Text] [Related]
5. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
[TBL] [Abstract][Full Text] [Related]
7. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of siRNA on bcr-abl gene expression in K562 cell line].
Jiang L; Wu JB; Yu K; Ni WH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):332-4. PubMed ID: 15228661
[TBL] [Abstract][Full Text] [Related]
9. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
10. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
11. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
Wang W; DU Y; Lin GQ; Li NN; Sun BZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
[TBL] [Abstract][Full Text] [Related]
12. miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL.
Liang B; Song Y; Zheng W; Ma W
Med Sci Monit; 2016 Aug; 22():2761-7. PubMed ID: 27492780
[TBL] [Abstract][Full Text] [Related]
13. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
[TBL] [Abstract][Full Text] [Related]
14. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
Wang W; Du Y; Li NN; Lv FF; Lin GQ
Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
[TBL] [Abstract][Full Text] [Related]
15. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Zhang JH; He YL; Zhu R; Du W; Xiao JH
Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
17. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
18. Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.
Gavrilov K; Seo YE; Tietjen GT; Cui J; Cheng CJ; Saltzman WM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6597-605. PubMed ID: 26627251
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
